Aspart-PH20: Final Phase I data

Final data from a double-blind, crossover, U.S. Phase I trial in 16 Type I diabetics who administered their insulin over 72 hours with an insulin pump showed that Aspart-PH20 significantly reduced glycemic excursion at 1, 1.5 and 2 hours post-meal vs. insulin aspart alone (p=0.0064, p=0.0062 and p=0.017, respectively). Data were presented at the American Diabetes Association meeting in San Diego. ...